Steve Michel | Sutro Biopharma, Inc.

Sutro to Present at 37th Annual J.P. Morgan Healthcare Conference

Sutro to Present at 37th Annual J.P. Morgan Healthcare Conference SOUTH SAN FRANCISCO, Calif., Jan. 3, 2019 –Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that Bill Newell, Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare...

Non-Confidential Corporate Presentation – JPM 2019

Presentations

Non-Confidential Corporate Presentation – JPM...

Sutro Achieves $10 Million Milestone Payment from Celgene

Press Releases

Sutro Achieves $10 Million Milestone Payment from Celgene Sutro develops successful spray drying technology marking a major advancement in commercial-scale manufacturing capabilities SOUTH SAN FRANCISCO, Calif., Dec. 19, 2018 — Sutro Biopharma, Inc. (NASDAQ:...

Sutro Biopharma Reports Third Quarter 2018 Financial Results

Press Releases

Sutro Biopharma Reports Third Quarter 2018 Financial Results — STRO-001 Received Orphan Drug Designation for Treatment of Multiple Myeloma — STRO-002 to Begin Phase 1 Trial for Patients with Ovarian and Endometrial Cancers in Early 2019 SOUTH SAN...

12th Biennial Ovarian Cancer Research Symposium – STRO-002 Abstract

Presentations

12th Biennial Ovarian Cancer Research Symposium – STRO-002 Abstract Objectives: Folate receptor alpha (FolRa) is a cell-surface glycoprotein, highly expressed in ovarian and endometrial adenocarcinoma, and is thus a promising target for cancer therapy using...

« Older Entries

Next Entries »